SEC Probes KV Pharmaceutical Stock Options

Law360, New York (March 26, 2008, 12:00 AM EDT) -- KV Pharmaceutical Company said Tuesday that its stock option program is under formal investigation by the U.S. Securities and Exchange Commission.

In a filing Tuesday with the SEC, the company said that it has cooperated with the SEC staff, providing copies of a company audit committee report and all documents collected in the course of the committee's review.

Recently, the SEC staff subpoenaed documents — many of which had already been produced — as part of its formal investigation, KV said. The commission also asked for...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.